| abstract |
The present invention relates to one or more SGLT2 inhibitors or pharmaceutically acceptable forms thereof for use in the treatment and / or prophylaxis of metabolic disorders in dogs, said metabolic disorders being preferably selected from the group consisting of ketosis, pre-diabetes, The present invention relates to the use of a compound of formula (I) for the manufacture of a medicament for the treatment of diabetes, insulin resistance diabetes mellitus, insulin resistance, obesity, hyperglycemia, hyperglycemia-induced cataract formation, impaired glucose tolerance, hyperinsulinemia, dyslipidemia, abnormal adipocyte certification, asymptomatic inflammation, Wherein the hyperglycemia-induced cataract is one or more disorders selected from the group consisting of inflammation, metabolic disorders such as hypertension, renal dysfunction and / or musculoskeletal disorders, and / or syndrome X (metabolic syndrome) Formation is prevented or remission is achieved and / or preferably the metabolic disorder results, for example, G., Prevent the occurrence of high blood pressure, renal dysfunction and / or musculoskeletal disorder, or is achieved or about progress is slowed down. |